US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04594031 |
|
Recruitment Status :
Withdrawn
(Preference given to gene therapy approaches by the SCD research community and patients' associations)
First Posted : October 20, 2020
Last Update Posted : July 5, 2022
|
Sponsor:
ExCellThera inc.
Collaborator:
California Institute for Regenerative Medicine (CIRM)
Information provided by (Responsible Party):
ExCellThera inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Estimated Primary Completion Date : | September 1, 2023 |
| Estimated Study Completion Date : | February 2, 2024 |